InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR).
Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.
Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.
Location: France, Pays de la Loire, Nantes
Employees: 1-10
Total raised: $6.82M
Founded date: 2013
Investors 1
| Date | Name | Website |
| - | GO Capital... | gocapital.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.06.2016 | Series A | $6.82M | - |
Mentions in press and media 3
| Date | Title | Description |
| 10.01.2022 | InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of Amyotrophic Lateral Sclerosis | Nantes, France--(Newsfile Corp. - January 10, 2022) - InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), receives approval fro... |
| 04.10.2021 | InFlectis BioScience Expands Leadership Team with Three Experienced International Appointments: Mark Pykett Is Appointed Chairman, Béatrice Lejeune Is Appointed Chief Regulatory Officer, and Prof. Bri... | Nantes, France--(Newsfile Corp. - October 4, 2021) - InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), expands its leadership... |
| 03.06.2016 | Biopharmaceutical Company InFlectis BioScience Raises €6M in Series A Funding | InFlectis BioScience SAS, a Nantes, France-based biopharmaceutical company specializing in the discovery and development of drugs for the treatment of protein misfolding diseases, completed €6m Series A financing round. The round was co-led... |